Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Transchem Ltd (TRANSCHEM)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 500422 NSE: TRANSCHEM Trading | Small Cap | Transchem Share Price
₹381.15 1.60 (0.42%)
As on 11-Sep'26 16:59
Transchem Ltd (TRANSCHEM)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 500422 NSE: TRANSCHEM Trading | Small Cap | Transchem Share Price
₹381.15 1.60 (0.42%)
As on 11-Sep'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹467 Cr.
Current Price
₹381.2
52-Week Low / High
₹56 / 388
TTM EPS
-
TTM Sales
-
Book Value per Share
-
P/E Ratio
Industry PE
40.3
Price to Book (P/B)
Price to Sales (P/S)
EV/EBITDA
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
%
Return on Capital Employed (ROCE)
%
Return on Assets (ROA)
%
Operating Profit Margin
0%
Net Profit Margin
-%
Gross Profit Margin
0%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
-
-100%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
56.45%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
-
Equity
₹12.2 Cr.
Face Value
₹10
All Time Low / High
₹2.55 / 384.00
Check Before You Invest
Quality
Not GoodValuation
OvervaluedCheck Valuation charts
Price Trend
Weak
Is Transchem Ltd a good quality company?
Transchem Ltd is a weak quality company, based on a inconsistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Transchem Ltd performance compare with that of its Peers?
Revenue growth of Transchem Ltd vs industry peers?
Transchem Ltd revenue CAGR is %, compared to the industry median CAGR of 10.23%, indicating slower growth and losing its market share.
Promoter shareholding and pledge status of Transchem Ltd?
Promoters hold 56.45% of the Transchem Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Transchem Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 36% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Transchem Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | -0.6% | -1.5% | 2.1% | 2.1% | 49.7% | 6.1% | 3.8% | 8% | 9.1% | 6.9% | - |
| Value Creation Index ⓘ | -1.0 | -1.1 | -0.9 | -0.9 | 2.6 | -0.6 | -0.7 | -0.4 | -0.4 | -0.5 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 0 | 0 | 0 | 0 | 22.5 | 0 | 0 | 0.4 | 2.6 | 0 | 0 |
| Sales YoY Gr. | - | NA | NA | NA | NA | -100% | NA | NA | 541.5% | -100% | - |
| Adj EPS ⓘ | -1.1 | -1.5 | 0.1 | 0.3 | 19.7 | 2.3 | 1 | 3.4 | 4 | 2.6 | 5.5 |
| YoY Gr. | - | NA | NA | 135.7% | 5878.8% | -88.1% | -56.8% | 239.6% | 16.3% | -34.3% | - |
| BVPS (₹) ⓘ | 31 | 30.1 | 31 | 30 | 51.4 | 54.2 | 53.8 | 61.8 | 64.8 | 68.3 | 71.1 |
| Adj Net Profit ⓘ | -1.3 | -1.8 | 0.2 | 0.4 | 24.2 | 2.9 | 1.2 | 4.2 | 4.9 | 3.2 | 7 |
| Cash Flow from Ops. ⓘ | 0.6 | -19.8 | 10.3 | -0.6 | -27.7 | 21.9 | 1.2 | -39.3 | 36 | -1.6 | - |
| Debt/CF from Ops. ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | -100% | NA | -100% | ||||
| Adj EPS ⓘ | NA | -33.2% | 37.4% | -34.3% | ||||
| BVPSⓘ | 9.2% | 5.8% | 8.3% | 5.4% | ||||
| Share Price | 36% | 76.7% | 152.1% | 542.2% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | -3.4 | -4.9 | 0.4 | 1.1 | 48.5 | 4.4 | 1.9 | 5.9 | 6.3 | 3.9 | 7.9 |
| Op. Profit Mgn % ⓘ | 0 | 0 | 0 | 0 | 91.4 | 0 | 0 | -423.4 | -55.7 | 0 | NAN |
| Net Profit Mgn % ⓘ | 0 | 0 | 0 | 0 | 107.5 | 0 | 0 | 1025.2 | 185.5 | 0 | INF |
| Debt to Equity ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Working Cap Days ⓘ | 0 | 0 | 0 | 0 | 457 | 0 | 0 | 40,246 | 7,099 | 0 | 0 |
| Cash Conv. Cycle ⓘ | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 183 | 209 | 0 | 0 |
Valuation of Transchem - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
No data found!
No data found!
No data found!
No data found!
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Transchem Ltd FAQs
The current trading price of Transchem on 11-Sep-2026 16:59 is ₹381.1.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 10-Sep-2026 the market cap of Transchem stood at ₹466.5 Cr
The latest P/E ratio of Transchem as of 10-Sep-2026 is 69.38.
The latest P/B ratio of Transchem as of 10-Sep-2026 is 5.36.
The 52-week high of Transchem is ₹388.0 and the 52-week low is ₹56.01.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Transchem is ₹0.00 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Transchem Ltd is a below average quality company.
The key valuation ratios of Transchem Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Transchem Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About Transchem Ltd
Transchem limited is a professionally managed, public limited company, the API manufacturing operations were started in 1993. The company is reputed as quality conscious manufacturer and exporter of specialized high quality API's and pharmaceutical intermediates.
The company is the largest producer of widest range of Anathematic API's (Anti-Parasitic) in the world, manufactured under one roof in WHO GMP accredited facility. It also offers specialized range of human use API’s.
The company is having four state of the art GMP approved facilities at multiple locations in
The company is one of the largest suppliers of Albendazole, Clorsulon, Diminazene Diaceturate, Toldimfos Sodium, Oxfendazole, Fenbendazole, Flubendazole, Mebendazole, Nitroxynil, Ramipril from India and can meet all the requiered technical and quality aspects of esteemed organizations and is now focusing on Anti-Hypertensive and Anti-Diabetic range of products.
Products and services offered by the company:
Services:
- Contract Research Facility.
- Custom Synthesis of Molecules.
- Contract Manufacturing of API's as per GMP Guidelines.
- Intermediates.
- Veterinary Formulations.
- Q.A. & Regulatory Support.
Product:
Anthelmintics
- Albendazole USP / EP /BP
- Ricobendazole (Albendazole Sulphoxide)
- Mebendazole EP / BP / USP / POLY 'C'
- Oxyclozanide BP VET
- Closantel Sodium EP / BASE
- Clorsulon USP
- Nitroscanate
- Fenbendazole EP/BP/BP VET
- Oxfendazole BP VET / EP
- Flubendazole EP / 98%
- Nitroxynil BP VET
- Rafoxanide BP VET
- Triclabendazole
- Praziquantel BP / USP
Veterinary API's
- Diminazene Diaceturate B VET C
- Quinapyramine Salts B VET C
- Parvaquone
- Toldimfos Sodium
- Acepromazine Maleate BP VET
- Butaphosphan
- Flunixin Meglumine USP
- Homidium Bromide / Chloride
- Isometamedium
Ectoparaciticides
- Cyromazine.
- Cymiazole
- S-Methoprene
- Azamethiphos.
Human Use API's
- Ramipril EP
- Frusemide EP / BP / USP
- Gabapentin USP
- Cetirizine DI HCL EP/BP
- Lamotrigine
- Pentamidine Isetionate BP
- Succinylcholine Chloride USP
- Epinastine HCL
- Nifuroxazide
You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
